novel transcript, antisense to C16orf45

The antisense transcript to C16orf45 (ENSG00000300371, LOC105371102) is listed as a “novel transcript” without experimental validation of its independent function, protein product, or clinical relevance. The "novel transcript" designation indicates an uncharacterized or predicted RNA, likely without protein product or known functional attributes in therapeutic contexts[3][5]. The associated sense gene, C16orf45 (also known as bMERB1), encodes a cytoplasmic and nuclear protein with high expression in the brain, thought to play a role in actin cytoskeleton and microtubule regulation, but this function is attributed to the protein-coding sense transcript, not the antisense. No evidence supports a therapeutic target role, disease association, or drug interaction for the antisense transcript[3][5]. It is not considered a recognized independent molecular target in biomedical literature. All functional and biomedical data refer to the gene/protein C16orf45/bMERB1 itself, not the antisense transcript. If a biological function, protein product, or clinically relevant attribute for this antisense transcript becomes recognized, its status as a target and details would need updating. If functional information on the protein-coding gene C16orf45/bMERB1 is sought, note that this entry refers to the antisense transcript, and only the sense gene/protein carries recognized function or therapeutic relevance[3].

Other names

C16orf45MINPENSG00000300371LOC105371102bMERB1